FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2911432854> ?p ?o ?g. }

• W2911432854 endingPage "274" @default.
• W2911432854 startingPage "268" @default.
• W2911432854 abstract "Aim: To study the effect of Ferroplat (FrP) on the indexes of pro/antioxidant balance and energy metabolism in breast cancer cells of different malignancy degree and different sensitivity to drug therapy. Materials and Methods: The study was carried out on breast cancer cells of low (T47D, MCF-7) and high malignancy degree (MCF-7/DDP (cisplatin-resistant), MDA-MB-231, MDA-MB-468) using cell culture techniques, immunocytochemical, biochemical, biophysical methods, flow cytometry and polarography. Results: We established that the addition of FrP to the culture medium reduces the activity of glucose-6-phosphate dehydrogenase (G6PDH), superoxide dismutase (SOD) and the level of non-protein thiols by 32–41% (p < 0.05). At the same time, there was an increase of the total level of ROS and the rate of NO generation by inducible NO synthase by 1.7–2.5 times (p < 0.05). This testifies that FrP disturbs the antioxidant balance in cells, resulting in their death. Also, the use of FrP led to a decrease in the rate of oxygen absorption in MCF-7 and T47D cells by 26% and 25%, respectively (p < 0.05). In cells of high malignancy degree this index decreased by 38–40% under the influence of FrP. Incubation of MCF-7 and T47D cells with the indicated agent also reduced the content of phospholipid cardiolipin by 15–16% (p < 0.05), and in MDA-MB-231, MCF-7/DDP, MDA-MB-468 cells — by 29%, 30% and 32%, respectively. In addition, the effect of FrP caused a decrease in the levels of Mg2+ and lactate in MCF-7 and T47D cells by 21–29% and 14–24%, respectively, whereas in MDA-MB-231, MDA-MB-468, MCF-7/DDP cells — by 34–38% and 32–35%, respectively. In this case, the agent raised the level of glucose in the cells of low malignancy degree by 20–23% (p < 0.05), and in the cells of high malignancy degree and with the phenotype of drug resistance — by 31–36%. However, the nanocomposite did not affect the activity of lactate dehydrogenase in all studied breast cancer cells. Conclusion: The study has shown that FrP has an effect on the pro/antioxidant balance and energy metabolism of cancer cells. In addition, the denoted effect of FrP was more pronounced in the breast cancer cells with a high malignancy degree and the phenotype of drug resistance." @default.
• W2911432854 created "2019-02-21" @default.
• W2911432854 creator A5002753137 @default.
• W2911432854 creator A5024765446 @default.
• W2911432854 creator A5027638389 @default.
• W2911432854 creator A5057262542 @default.
• W2911432854 creator A5079870216 @default.
• W2911432854 creator A5081677452 @default.
• W2911432854 creator A5085291205 @default.
• W2911432854 date "2018-12-22" @default.
• W2911432854 modified "2023-10-06" @default.
• W2911432854 title "INFLUENCE OF FERROMAGNETIC NANOCOMPOSITE (FERROPLAT) ON HUMAN BREAST CANCER CELLS OF DIFFERENT MALIGNANCY DEGREES: PRO/ANTIOXIDANT BALANCE AND ENERGY METABOLISM" @default.
• W2911432854 doi "https://doi.org/10.31768/2312-8852.2018.40(4):268-274" @default.
• W2911432854 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30593756" @default.
• W2911432854 hasPublicationYear "2018" @default.
• W2911432854 type Work @default.
• W2911432854 sameAs 2911432854 @default.
• W2911432854 citedByCount "1" @default.
• W2911432854 countsByYear W29114328542023 @default.
• W2911432854 crossrefType "journal-article" @default.
• W2911432854 hasAuthorship W2911432854A5002753137 @default.
• W2911432854 hasAuthorship W2911432854A5024765446 @default.
• W2911432854 hasAuthorship W2911432854A5027638389 @default.
• W2911432854 hasAuthorship W2911432854A5057262542 @default.
• W2911432854 hasAuthorship W2911432854A5079870216 @default.
• W2911432854 hasAuthorship W2911432854A5081677452 @default.
• W2911432854 hasAuthorship W2911432854A5085291205 @default.
• W2911432854 hasConcept C121608353 @default.
• W2911432854 hasConcept C126322002 @default.
• W2911432854 hasConcept C185592680 @default.
• W2911432854 hasConcept C190283241 @default.
• W2911432854 hasConcept C2775838275 @default.
• W2911432854 hasConcept C2778004101 @default.
• W2911432854 hasConcept C2779399171 @default.
• W2911432854 hasConcept C530470458 @default.
• W2911432854 hasConcept C55493867 @default.
• W2911432854 hasConcept C71924100 @default.
• W2911432854 hasConcept C96232424 @default.
• W2911432854 hasConceptScore W2911432854C121608353 @default.
• W2911432854 hasConceptScore W2911432854C126322002 @default.
• W2911432854 hasConceptScore W2911432854C185592680 @default.
• W2911432854 hasConceptScore W2911432854C190283241 @default.
• W2911432854 hasConceptScore W2911432854C2775838275 @default.
• W2911432854 hasConceptScore W2911432854C2778004101 @default.
• W2911432854 hasConceptScore W2911432854C2779399171 @default.
• W2911432854 hasConceptScore W2911432854C530470458 @default.
• W2911432854 hasConceptScore W2911432854C55493867 @default.
• W2911432854 hasConceptScore W2911432854C71924100 @default.
• W2911432854 hasConceptScore W2911432854C96232424 @default.
• W2911432854 hasIssue "4" @default.
• W2911432854 hasLocation W29114328541 @default.
• W2911432854 hasLocation W29114328542 @default.
• W2911432854 hasOpenAccess W2911432854 @default.
• W2911432854 hasPrimaryLocation W29114328541 @default.
• W2911432854 hasRelatedWork W1942868 @default.
• W2911432854 hasRelatedWork W1981600545 @default.
• W2911432854 hasRelatedWork W1992390260 @default.
• W2911432854 hasRelatedWork W2010684987 @default.
• W2911432854 hasRelatedWork W2341629494 @default.
• W2911432854 hasRelatedWork W2386605958 @default.
• W2911432854 hasRelatedWork W2501960686 @default.
• W2911432854 hasRelatedWork W2569030526 @default.
• W2911432854 hasRelatedWork W3012168770 @default.
• W2911432854 hasRelatedWork W3156932517 @default.
• W2911432854 hasVolume "40" @default.
• W2911432854 isParatext "false" @default.
• W2911432854 isRetracted "false" @default.
• W2911432854 magId "2911432854" @default.
• W2911432854 workType "article" @default.